Navigation Links
Tracleer(R) Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension
Date:10/23/2007

- Studies Show Improvement in Hemodynamics and Delay Disease Progression -

CHICAGO, Oct. 23 /PRNewswire/ -- Actelion Pharmaceuticals US, Inc. today announced positive results from two trials demonstrating that Tracleer(R) (bosentan) may be safe and effective as a combination therapy for the treatment of pulmonary arterial hypertension (PAH). Data from both studies suggest that Tracleer, when given in combination with sildenafil, is well-tolerated and improves hemodynamics in PAH patients. The data were presented at CHEST 2007, the annual meeting of the American College of Chest Physicians, taking place in Chicago.

COMPASS-1 (Effects of Combination Of bosentan and sildenafil versus sildenafil Monotherapy on morbidity and mortality in symptomatic PAtientS with pulmonary arterial hypertenSion) was the first clinical trial to provide detailed hemodynamic information on the combination of Tracleer and sildenafil, and showed that the combination of acute oral sildenafil together with long-term Tracleer therapy significantly reduced pulmonary vascular resistance (PVR).

Data from the sildenafil cohort of the Phase 3 EARLY (Endothelin Antagonist tRial in miLdlY symptomatic PAH patients) study showed that Tracleer improved hemodynamics and suggested a delay in disease progression in sildenafil-treated mildly symptomatic PAH patients. The EARLY trial was the first study of its kind to evaluate the benefit of Tracleer and sildenafil combination therapy.

"Despite the availability of effective PAH therapies, we are not meeting key treatment goals for long-term stabilization in the majority of patients," said Nazzareno Galie from the University of Bologna, Italy, also the lead author of the COMPASS-1 study. "Given the progressive and destructive nature of this disease, combining therapies with different modes of action has become an important focus for research, and these results support our belief that adding bosentan to sildenafil could potentially s
'/>"/>

SOURCE Actelion Pharmaceuticals US, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
2. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
5. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
6. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
7. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
8. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
11. New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... BRIDGEWATER, N.J. , Sept. 16, 2014 /PRNewswire/ ... pharmaceutical company focused on developing and commercializing therapeutic ... renal and infectious diseases, announces the amendment and ... and E preferred stock and related warrants, as ... 2014 common stock and warrant financing, to remove ...
(Date:9/16/2014)... Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY ... quality and novel medicines to physicians and patients at ... Mark Baum will be a presenter at the ... New York City.  Mr. Baum will discuss the company,s ... in ophthalmology. The presentation is scheduled for 10:40 a.m. EST ...
(Date:9/16/2014)... Sept. 16, 2014  Wearable sports and activity ... less than two years, producing a massive amount ... huge opportunity exists for leveraging this data to ... ) introduced a first-of-its-kind wearable analytics platform for ... of clinical research linking activity and health risks, ...
Breaking Medicine Technology:CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 2CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 3Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 2Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 3Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 4Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 2Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 3
... Inc., a pioneer in the area of digital PCR, is ... to evaluate the capabilities of digital PCR and see the ... will start on Monday, September 12 in Boston and finish ... The QuantaLife ddPCR System claims to be the world,s most ...
... SILVER SPRING, Md., Aug. 26, 2011 The FDA ... ensuring the safety of their food and medical supplies ... week,s expected hurricane-related rain, possible flooding and power outages. ... The agency also reminds consumers that it is important ...
Cached Medicine Technology:QuantaLife™ Kicks Off Droplet Digital™ PCR Road Show 2FDA Hurricane Preparedness Checklist 2FDA Hurricane Preparedness Checklist 3FDA Hurricane Preparedness Checklist 4
(Date:9/16/2014)... use among teens in the United States is on the ... the new study also found that alcohol use, binge drinking ... the ages of 12 and 17 also dropped between 2002 ... 12 and older across the United States revealed that between ... age group also dropped from 8.9 percent to 5.2 percent. ...
(Date:9/16/2014)... equally preserved in cancer patients suffering from malignant spinal ... 10 Gy of radiation therapy (RT), compared to patients ... RT each, according to research presented today at the ... , Malignant spinal cord compression (MSCC) is a ... occurs when a tumor,s secondary deposit presses on the ...
(Date:9/16/2014)... to be on the heavy side. Researchers at the ... seven in every ten obese adults underestimate how much ... much less often. Mothers of overweight or obese children ... misjudge their obese mothers, size, says lead author Tracy ... in the Journal of General Internal Medicine , ...
(Date:9/16/2014)... -- While abnormalities in the adrenergic and noradrenergic ... thought to play a role in the development ... has been no genetic evidence of this connection. ... Columbia University,s Mailman School of Public Health and ... the ADRB2 gene and childhood adversity. For individuals ...
(Date:9/16/2014)... The Pain Center of Arizona (TPC), ... has selected Analance ™, Ducen ’s BI ... TPC seeing hundreds of thousands of patients annually, the ... through “home grown” systems trying to piece together actionable ... “Our current tools were not scalable and, in ...
Breaking Medicine News(10 mins):Health News:Fewer U.S. Teens Using Illegal Drugs and Alcohol, Report Finds 2Health News:Cancer patients with malignant spinal cord compression have preserved mobility 2Health News:Cancer patients with malignant spinal cord compression have preserved mobility 3Health News:Cancer patients with malignant spinal cord compression have preserved mobility 4Health News:Poor body size judgement can lead to increased tolerance of obesity 2Health News:Evidence of genetic link to PTSD in soldiers exposed to childhood trauma 2Health News:Evidence of genetic link to PTSD in soldiers exposed to childhood trauma 3Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 2Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 3
... leading neuromodulation company, announced today that beginning January ... by Medicare for incomplete spinal cord injury patients ... Centers for Medicare and Medicaid Services (CMS) establishes ... stimulation (FES) devices including the NESS L300™ Foot ...
... changed in a heartbeat for successful freelance writer Lee Woodruff ... Tonight, was wounded while broadcasting from Iraq. Her experience as ... be the focus of her keynote address at URAC,s Best ... Exhibit, April 1-2, 2009 in Orlando, Fla. , ...
... 11 Rosalind Franklin University,of Medicine and Science ... the first in the nation to provide its students with ... The new,system enables medical educators to present students with individual ... has a proven,accuracy rate of over 90 percent. , ...
... Pain Therapeutics, Inc. (Nasdaq: PTIE ) has received a ... for its New Drug Application (NDA) for REMOXY(R), an abuse-resistant controlled-release ... determined that the NDA is not approved in its present form. ... believes additional non-clinical data will be required to support the approval ...
... 11 Preferred Management Corporation of,Shawnee, OK ... two hospitals near Amarillo, Texas. The hospitals, ... General Hospital in Wellington, are both,federally designated ... are administered by Preferred Management Corporation which ...
... to be ignoring message that methamphetamine is dangerous , , ... that utilizes graphic images actually may not be very ... Project (MMP), created in 2005, featured images that showed ... perceived success of the program had resulted in its ...
Cached Medicine News:Health News: Medicare to Reimburse for the Bioness L300™ Foot Drop System for Spinal Cord Injury 2Health News: Medicare to Reimburse for the Bioness L300™ Foot Drop System for Spinal Cord Injury 3Health News:Best-selling Author Lee Woodruff, Futurist Ian Morrison to Speak at URAC's Best Practices Conference 2Health News:Best-selling Author Lee Woodruff, Futurist Ian Morrison to Speak at URAC's Best Practices Conference 3Health News:Rosalind Franklin University of Medicine and Science First in Illinois to Equip Students With Computerized Diagnosis System 2Health News:Pain Therapeutics Receives Complete Response Letter From FDA for REMOXY(R) 2Health News:Pain Therapeutics Receives Complete Response Letter From FDA for REMOXY(R) 3Health News:Preferred Management Corp. Installs OpusClinicalSuite(R) at 2 Texas Hospitals 2Health News:Preferred Management Corp. Installs OpusClinicalSuite(R) at 2 Texas Hospitals 3Health News:Study Questions Value of Anti-Meth Campaign 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: